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Upon infection, the herpes simplex virus (HSV) transcriptional activator VP16 directs the formation of a
multiprotein-DNA complex—the VP16-induced complex—with two cellular proteins, the host cell factor HCF-1
and the POU domain transcription factor Oct-1, on TAATGARAT-containing sequences found in the promot-
ers of HSV immediate-early genes. HSV VP16 contains carboxy-terminal sequences important for transcrip-
tional activation and a central conserved core that is important for VP16-induced complex assembly. On its
own, VP16 displays little, if any, sequence-specific DNA-binding activity. We show here that, within the
VP16-induced complex, however, the VP16 core has an important role in DNA binding. Mutation of basic
residues on the surface of the VP16 core reveals a novel DNA-binding surface with essential residues which are
conserved among VP16 orthologs. These results illuminate how, through association with DNA, VP16 is able
to interpret cis-regulatory signals in the DNA to direct the assembly of a multiprotein-DNA transcriptional
regulatory complex.
In eukaryotes, regulation of gene expression often involves
the assembly of multiprotein-DNA complexes consisting of
trans-acting proteins, called transcription factors, bound to cis-
acting DNA elements in promoters. To assemble a proper
transcriptional regulatory complex, transcription factors must
recognize and interpret regulatory signals encoded in the
DNA. An example of such a multiprotein transcriptional reg-
ulatory complex is the herpes simplex virus (HSV) VP16-in-
duced complex, which regulates the transcription of HSV im-
mediate-early (IE) genes.
The VP16-induced complex is composed of three proteins—
the viral protein VP16 and two cellular proteins, HCF-1 and
Oct-1 (see references 14, 31, and 43 for reviews). Upon HSV
infection, VP16 (also known as aTIF and Vmw65), a compo-
nent of the virus particle, is released into the cell, where it first
binds to HCF-1 (17, 20, 37, 50), a protein involved in cell
proliferation (9). HCF-1 (also known as HCF, C1, VCAF, and
CFF) is a dimeric complex of polypeptides that arises from
internal proteolytic cleavage of a single large precursor protein
of over 2,000 amino acids (22, 48, 49). Although HCF-1 is large
and complex, its amino-terminal 380 residues are sufficient for
association with VP16 and VP16-induced complex formation
(23, 47).
HCF-1 association with VP16 leads to the subsequent inter-
action of the VP16–HCF-1 complex with Oct-1 on DNA, cre-
ating a multiprotein HCF-1–VP16–Oct-1–DNA complex on
VP16 IE gene response elements. Oct-1 is a broadly expressed
transcription factor that binds the octamer sequence ATGCA
AAT with high affinity through a POU DNA-binding domain
(12, 39). The POU domain is a bipartite DNA-binding domain
composed of an amino-terminal POU-specific domain and a
carboxy-terminal POU homeodomain, joined by a flexible
linker region (18, 40). Residues on the solvent-exposed surface
of the Oct-1 POU homeodomain direct VP16-induced com-
plex formation (24, 34, 38).
The cis-regulatory target of the VP16-induced complex is
referred to as the TAATGARAT element because it often
contains the core consensus sequence TAATGARAT (where
R is purine). TAATGARAT elements contain three sequence
determinants important for VP16-induced complex formation.
First, the TAAT segment is involved in Oct-1 POU homeo-
domain binding; many, but not all, TAATGARAT response
elements also contain an adjacent 59 ATGC POU-specific do-
main binding site (ATGCTAATGARAT), which also contrib-
utes to Oct-1 DNA binding (1, 4, 6). Second, the GARAT
sequence is important for VP16-induced complex formation
but not necessarily Oct-1 binding—some point mutations
within the GARAT sequence disrupt VP16-induced complex
formation with little, if any, effect on the affinity of Oct-1 for
the TAATGARAT element (8, 19, 32, 37). Third, the D ele-
ment, a short 3-bp sequence located 39 of the GARAT ele-
ment, is also involved in VP16-induced complex formation and
can determine the selectivity of VP16 association with TAAT
GARAT elements by different VP16 orthologs, in particular,
the HSV-1 and bovine herpesvirus type 1 (BHV-1) VP16 pro-
teins (16, 29).
Like other transcription factors, HSV-1 VP16, a 490-amino-
acid protein, has a modular structure (5, 35, 44). It contains a
carboxy-terminal transcriptional activation domain and a cen-
tral conserved core (residues 49 to 385), which is sufficient for
VP16-induced complex formation (10, 27). Recently, the crys-
tal structure of the conserved core (residues 49 to 412) was
solved to 2.1 Å resolution (27), revealing a protein with a novel
structure containing ordered (residues 49 to 349) and disor-
dered (residues 350 to 394) regions important for VP16-in-
duced complex formation and two small ordered (residues 395
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to 402) and disordered (residues 403 to 412) regions which are
dispensable for VP16-induced complex formation. The larger
disordered region has been analyzed extensively by mutagen-
esis, by protease sensitivity, and with synthetic peptides (see
reference 25 for references); it is involved in interactions with
each of the other components of the VP16-induced complex—
HCF-1, Oct-1, and DNA—and probably adopts an ordered
structure upon VP16-induced complex formation. In contrast,
the large ordered region, which has a structure resembling a
seat, has been much less well characterized, although it is
known to be involved in recognition, either directly or indi-
rectly, of the D element (27).
VP16 has little DNA-binding activity on its own, which has
made analysis of its DNA-binding activity difficult (20, 28, 37,
45). Thus, the mechanism by which VP16 recognizes DNA
within the VP16-induced complex is unknown, and models for
direct (6, 13, 20, 27, 32, 43) and indirect (29, 45) recognition of
DNA have been proposed. Here, we describe molecular stud-
ies that support the model for direct DNA contact by VP16 in
the VP16-induced complex. Our results show that, on a TAAT
GARAT site, VP16 is positioned over the D element adjacent
to the Oct-1 POU domain. VP16 associates with the DNA
through a novel DNA-binding surface, indicating that one role
for VP16 in assembly of the VP16-induced transcriptional reg-
ulatory complex is DNA binding.
MATERIALS AND METHODS
Expression constructs. Plasmids pNCITE-HCF-1N380 (47), pET11c.G.POU-1
(24), pET11c.ori1(2)/VP1649–412 (27), pET11c.ori1(2)/VP16DC, pCGNVP16
(25), pU2/b 6xTAAT-1 (2), and pa4x(A1C) (42) have been described previ-
ously. Full-length VP16 for expression in Escherichia coli was generated by
transferring the VP16 coding sequence (residues 5 to 490) as an XbaI-BamHI
DNA fragment from pCGNVP16 into the 59 XbaI and 39 BamHI sites of
pET11c.ori1(2); creating the plasmid pET11c.ori1(2)/VP16. For HCF-1 syn-
thesis in E. coli, the XbaI-BamHI DNA fragment from pNCITE-HCF-1N380
(amino acids 2 to 380) was inserted into the 59 NheI and 39 BamHI sites of
pET28a(1) (Novagen), creating the plasmid pET28a(1)/HCF-1N380. For HCF-1
synthesis in baculovirus-infected Sf9 cells, HCF-1N380 sequences were amplified
by PCR and inserted into the 59 XbaI and 39 BamHI sites of the modified
baculovirus transfer vector pAcUW51 (11) such that the HCF-1 open reading
frame continued into 10 in-frame histidine codons 39 of the BamHI site.
VP16 mutagenesis. Mutant VP16DC expression plasmids were generated by oli-
gonucleotide-mediated site-directed mutagenesis of the plasmid pET11c.ori1
(2)/VP16DC, which encodes HSV-1 VP16 (residues 5 to 412) fused to the
glutathione S-transferase (GST) gene product. The mutations are named ac-
cording to the identity of the wild-type amino acid, followed by its position in
VP16 and the identity of the amino acid substitution. The following sequences
were created to generate the mutant proteins: R64A, AAC gcg tTa CTC (MluI);
R100A, TAC gcG GAG (BstUI); K103A, TGc gcA TTC (FspI); R129A, ATT
gcC GCC (Fnu4HI); R143A, ACa gct GAC (PvuII); R155A, CTC TCa GcT
(DdeI); R184A, CTa gcC GCC (BfaI); R208A, ATG CTa gcC (NheI); R214A,
GAC gcG TAC (MluI); R217A, TAC gct GAG (DdeI); R221A, GCa gcg CTG
(Eco47III); R224, GCG gcg GTT (EaeI); R236A, ACC gcg GAG (SacII);
R290A, GCC gcg CGc CTG (BssHII). In this notation scheme, the bases that are
altered in wild-type VP16 are shown in lowercase, the new amino acid codon is
in boldface, and the engineered restriction site for the nuclease indicated in
parentheses is underlined. The mutations E361A/385Ala3, 366Ala3, and G374A
have been described previously (25). The deletion mutations were generated by
oligonucleotide-mediated loop-out mutagenesis by using oligonucleotides D198–
201 (CAGGCGCACATGCGCGACCTGGGAGAAATG) and D187–206 (TAC
CTGCGCGCCAGCCTGCGCGCCACGATC). Mutant pCGNVP16 expression
plasmids were generated by the QuikChange site-directed mutagenesis protocol
(Stratagene). All mutations were verified by DNA sequence analysis.
Protein synthesis and purification. Wild-type and mutant VP16 proteins and
the Oct-1 POU domain were synthesized as GST fusion proteins and purified
from E. coli BL21(DE3) as described previously (24). The GST moiety of the
GST-VP16 fusion proteins used in the experiments whose results are shown in
Fig. 2 to 4 and of the Oct-1 POU domain was removed by thrombin digestion.
HCF-1N380 used in the experiment whose results are shown in Fig. 2 was
synthesized and purified from E. coli BL21(DE3). Typically, cells grown contin-
uously at 18°C to an optical density at 600 nm of 0.4 to 0.6 were induced at 18°C
for ;12 h with 0.4 mM isopropyl-b-D-thiogalactopyranoside. The cells were
harvested by centrifugation and resuspended in 1/10 volume of the culture
medium with a buffer containing 50 mM NaH2PO4 (pH 8.0), 300 mM NaCl, 20%
glycerol, and 10 mM imidazole. Following lysozyme treatment, NP-40 was added
to 0.1% and the lysate was sonicated five times with 40-s pulses (20% duty on a
Tekmar CV26 sonicator). Insoluble material was removed by centrifugation.
Soluble histidine-tagged proteins were bound to Ni-nitrilotriacetic acid agarose
(Qiagen) at 4°C for 2 h, washed, and subsequently eluted with 500 mM imidazole
in 50 mM NaH2PO4 (pH 8.0)–300 mM NaCl–20% glycerol. Protein integrity,
purity, and relative concentration were determined by Coomassie blue staining
after sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE).
The HCF-1N380 used in subsequent experiments was produced in baculovirus-
infected Sf9 cells. Recombinant HCF-1N380-containing viruses were generated
from an HCF-1N380-containing transfer vector by using a BaculoGold transfec-
tion kit (Pharmigen). Positive viruses were plaque purified twice and amplified.
Sf9 cells were infected at a multiplicity of infection of 10, and cells were har-
vested 36 h postinfection. Cells (5 3 107) were washed and lysed in 1 ml of a
buffer containing 10 mM Tris (pH 7.6), 10 mM NaH2PO4 (pH 7.6), 500 mM
NaCl, 10 mM NaF, 10 mM Na pyrophosphate, 5 mM 2-mercaptoethanol, 1%
Triton X-100, 10% glycerol, 500 mg of Pefablock per ml, and 10 mM imidazole
for 1 h on ice with periodic vortexing. Cellular debris was removed by centrifu-
gation, and the remaining lysate was dialyzed for ;12 h against buffer BAC (10
mM Tris [pH 8.0], 10 mM NaH2PO4 [pH 8.0], 500 mM NaCl, 5 mM 2-mercap-
toethanol, 10% glycerol, 500 mg of Pefablock per ml, 10 mM imidazole). Histi-
dine-tagged proteins were bound to Ni-nitrilotriacetic acid agarose (Qiagen) at
4°C for 3 h, washed twice with 10 bead volumes of buffer BAC containing 50 mM
imidazole, eluted with buffer BAC containing 1 M imidazole, and collected in
;0.5-ml fractions. Protein integrity, concentration, and purity were judged by
VP16-induced complex formation, Western blotting using the anti-HCF-1N18
antibody (9), and Coomassie blue staining after SDS-PAGE. For proteins used
in immunoprecipitations, VP16DC and HCF-1N380 were synthesized by tran-
scription and translation in vitro as described previously (3, 47). HeLa cell
nuclear extract was a kind gift of Xuemei Zhao, Cold Spring Harbor Laboratory.
DNase I protection analysis. Protein-DNA binding was performed in 50-ml
reaction mixtures containing 2 3 104 cpm of DNA probe, 10 mM Tris-HCl (pH
7.9), 50 mM KCl, 2 mM dithiothreitol, 1 mM EDTA, 0.1% NP-40, 2% glycerol,
2% Ficoll, 3 mg of fetal bovine serum per ml, 50 ng of fish sperm DNA, 8.0 mg
of unsonicated poly(dI-dC) (Pharmacia), and 2% polyvinyl alcohol. The purified
recombinant Oct-1 POU domain (40 ng), VP16 (80 ng), HCF-1N380 (4 ml), and
HeLa cell nuclear extract (35 mg) were used as indicated in Results. Reaction
mixtures were processed as described previously (2).
Coimmunoprecipitation assays. In vitro-translated hemagglutinin (HA)-
tagged HCF-1N380 (5 ml) and VP16DC (5 ml) were mixed in 40 ml of 50 mM Tris
(pH 8.0)–200 mM KCl–1 mM EDTA–0.05% NP-40–1 mM phenylmethylsulfonyl
fluoride and incubated at 4°C for 30 min with rotation. Subsequently, 10 ml of
precoupled anti-HA antibody (12CA5)–protein G–agarose beads was added and
allowed to incubate for a further 2 h at 4°C with rotation. After incubation, the
beads were washed four times with 500 ml of 50 mM Tris (pH 8.0)–200 mM
KCl–1 mM EDTA–0.05% NP-40–1 mM phenylmethylsulfonyl fluoride and com-
plexes were resolved by SDS–8% PAGE and visualized by fluorography.
Electrophoretic mobility retardation assays. VP16-induced complex forma-
tion assays were performed under conditions described previously (25), with the
following modifications. For the experiment whose results are shown in Fig. 2A,
;2 mg of HeLa cell nuclear extract and 20 ng of full-length VP16 were used, and
for Fig. 2B, 10 ng each of Oct-1 POU, VP1649–412, and HCF-1N380 were used as
indicated. For Fig. 5, 25 ng of wild-type or mutant GST-VP16DC, 5 ng of Oct-1
POU domain, and 0.5 ml of baculovirus expressed HCF-1N380 were used. For
VP16–Oct-1–DNA complex formation assays, GST-VP16DC (200 ng) and the
Oct-1 POU domain (0.1 ng) were incubated with 2 3 104 cpm of DNA probe, as
indicated, in 10 mM Tris-HCl (pH 7.9)–50 mM KCl–2 mM dithiothreitol–1 mM
EDTA–0.1% NP-40–2% glycerol–2% Ficoll–100 mg of bovine serum albumin–10
ng of fish sperm DNA–10 ng of unsonicated poly(dI-dC) (Pharmacia) for 30 min
at 30°C. After incubation, the reaction mixtures were loaded onto a 6% poly-
acrylamide gel (acrylamide-bisacrylamide ratio, 19:1) in 0.253 TBE (22.5 mM
Tris-borate, 0.5 mM EDTA) which had been subjected to prior electrophoresis
for 30 min at room temperature. For VP16-DNA complex formation assays, a
larger amount of VP16 (;1 mg) was used and incubated under the same condi-
tions as for the VP16–Oct-1–DNA complex formation assay. After incubation,
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the reaction mixtures were loaded onto a 3% glycerol–6% polyacrylamide gel
(acrylamide-bisacrylamide ratio, 39:1) in 0.253 TBE which had been subjected
to prior electrophoresis for 30 min at room temperature.
In vivo transcription assays. HeLa cells were seeded at 5 3 105/10-cm-diam-
eter dish and transfected after 24 h with 2 mg of reporter plasmid pU2/
b6xTAAT-1 150 ng of internal reference plasmid pa4x(A1C), and 1 mg of
wild-type or mutant expression plasmid pCGNVP16 by using FUGENE 6 trans-
fection reagent (Roche) in accordance with manufacturer’s recommendations.
To assay reporter gene expression, cytoplasmic RNA was isolated and analyzed
by RNase protection (41) with the a98 and b134 probes (2). Unprotected RNA
was digested with RNases A and T1, and protected fragments were visualized by
denaturing PAGE. Levels of reporter gene expression were quantified on a Fuji
BAS1000 phosphorimager. Expression of epitope-tagged VP16 proteins was
measured by immunoblot analysis using the monoclonal antibody 12CA5. All
proteins were expressed at similar levels.
RESULTS
We have analyzed how VP16 recognizes DNA within the
VP16-induced complex. Figure 1 illustrates the four compo-
nents of the VP16-induced complex: the cis-regulatory TAAT
GARAT element (Fig. 1A) and the three trans-acting proteins
VP16, Oct-1, and HCF-1 (Fig. 1B). Figure 1C and D show two
views, the front and left, respectively, of the determined VP16
core structure (27). The TAATGARAT element derives from
the HSV-1 ICP0 IE gene promoter and contains an imperfect
TAATGARAT core sequence (TAATGATAT) and an imper-
fect overlapping ATGCTAAT octamer sequence (imperfec-
tions underlined), for which it is referred to as an (OCTA1)T
AATGARAT site. On the 39 side of the TAATGARAT core
sequence is the three-nucleotide D element sequence CTT,
which is responsible for differential recognition of TAATGA
RAT elements by the HSV-1 and BHV-1 VP16 proteins (16).
Figure 1B shows a scaled schematic of VP16, Oct-1, and
HCF-1. The minimal regions required for VP16-induced com-
plex formation determined previously (10, 19, 23, 27, 38, 47)
are highlighted in black.
A VP16-induced complex can be assembled from recombi-
nant proteins synthesized in E. coli. Figure 2A illustrates the
assembly of a VP16-induced complex using a HeLa cell nuclear
extract as a source of native Oct-1 and HCF-1 and full-length
VP16 synthesized in E. coli. VP16-induced complex formation
was measured in an electrophoretic mobility retardation assay
using the ICP0 (OCTA1)TAATGARAT site. As expected,
VP16 alone failed to bind the (OCTA1)TAATGARAT probe
effectively (compare lanes 1 and 2). Addition of HeLa cell
nuclear extract generated an Oct-1–DNA complex (lane 3;
labeled Oct-1), and further addition of VP16 generated the
slower-migrating VP16-induced complex (lane 4; labeled
VIC).
In contrast to VP16-induced complex assembly with native
human HCF-1 and Oct-1 proteins as shown in Fig. 2A, at-
tempts to assemble a VP16-induced complex with all three
protein components prepared from E. coli have reportedly
failed (23, 33). These and other results (21, 33) have led to the
suggestion that eukaryotic cell-specific posttranslational mod-
ifications may be required for VP16-induced complex assem-
bly. In preliminary experiments, we found the synthesis of the
HCF-1 VP16 interaction domain (VID) in E. coli in an active
form to be difficult to achieve. By lowering the temperature at
which E. coli synthesizes the HCF-1N380 VID-containing pro-
tein (residues 1 to 380; Fig. 1B), however, we were able to
obtain soluble and active HCF-1N380 protein. By using this
HCF-1N380 protein and the Oct-1 POU domain (residues 280
to 438) and VP1649–412 core (residues 49 to 412) proteins (Fig.
1B) also synthesized in E. coli, we examined whether the min-
imal regions of VP16, Oct-1, and HCF-1 synthesized solely in
E. coli can form a VP16-induced complex.
Figure 2B shows the activity of the E. coli-synthesized min-
imal-region proteins used at approximately equimolar levels
(10 ng of each protein). Neither the minimal VP16 (VP1649–412)
protein nor the minimal HCF-1 (HCF-1N380) protein, alone or
in combination, bound the DNA probe, as expected (compare
lanes 1 to 4). In contrast, the Oct-1 POU domain bound the
(OCTA1)TAATGARAT probe to form an Oct-1 POU do-
main–DNA complex with a majority of the probe (lane 5;
labeled Oct-1 POU). Further addition of either VP1649–412 or
HCF-1N380 alone did not affect the Oct-1 POU domain–DNA
complex (lanes 6 and 7). When all three E. coli-derived
VP1649–412, HCF-1N380, and Oct-1 POU domain proteins were
added together, however, efficient levels of VP16-induced
complex formation were achieved (lane 8; labeled mini-VIC).
Thus, a VP16-induced complex can be faithfully and efficiently
reproduced in vitro by using proteins that have been synthe-
sized in E. coli. We conclude, therefore, that no eukaryotic
cell-specific protein modifications are essential for the minimal
regions of VP16, HCF-1, and Oct-1 to form a VP16-induced
complex. These results validate the use of E. coli-derived pro-
teins for the analysis of VP16-induced complex formation.
A minimal VP16-induced complex produces an extended
DNase I protection pattern. Previous DNA cleavage protec-
tion studies have shown that, on (OCTA1)TAATGARAT and
related sites, Oct-1 alone protects nucleotides centered over
the octamer sequence and addition of VP16 and HCF-1 ex-
tends the Oct-1 protection pattern unidirectionally over the
entire TAATGARAT element, including the D element (Fig.
1A) (2, 19, 20, 45). The component of the VP16-induced com-
plex responsible for extension of the protection pattern is not
known. One explanation for the extension is that it represents
nonspecific interactions, resulting simply from the creation of a
large multiprotein complex. To determine if the regions of
HCF-1, Oct-1, and VP16 that are dispensable for VP16-in-
duced complex formation are responsible for the extended
footprint, we compared the DNase I protection patterns of
VP16-induced complexes assembled from full-length proteins
with those of complexes assembled from recombinant mini-
mal-region proteins.
Figure 3A shows the DNase I protection pattern produced
by the native complex of full-length proteins. As expected,
addition of VP16 alone did not affect the DNase I cleavage
pattern of naked DNA (compare lanes 1 and 2). Addition of
HeLa cell nuclear extract resulted in weak protection of the
octamer sequence (lane 3), but further addition of VP16 en-
hanced the footprint over the entire octamer (TAATGARAT)
and D element sequences (compare lanes 3 and 4). Figure 3B
shows the protection pattern produced by the recombinant
minimal-region proteins. Addition of VP1649–412 and HCF-
1N380, either alone or in combination, failed to protect the
DNA probe (lanes 2 to 4). At the concentrations of protein
used in this experiment, the Oct-1 POU domain alone (lane 5)
or in the presence of either VP1649–412 or HCF-1N380 (lanes 6
and 7) produced little protection of the TAATGARAT ele-
ment. A 10-fold higher concentration of the Oct-1 POU do-
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FIG. 1. Representation of TAATGARAT and VP16-induced complex components. (A) Nucleotide sequence of an (OCTA1)TAATGARAT
element from the HSV-1 ICP0 promoter. The octamer TAATGARAT and D elements are indicated by the brackets. 3, nucleotide substitution
from a consensus site. (B) Structural features of the three proteins, VP16, Oct-1, and HCF-1, required for VP16-induced complex formation. The
minimal domain within each protein that is required for VP16-induced complex formation is shown in black, and the amino acid boundries are
indicated by the double-headed arrow. Regions such as the VP16 transcriptional activation domain (AD), the Oct-1 amino- and carboxy-terminal
transcriptional activation domains (Q and S/T, respectively), the HCF-1 Fn3 repeats (rep.); and regions enriched in basic or acidic amino acids are
highlighted in gray. The positions of the six nearly perfect (filled arrowheads) and two nonfunctional (open arrowheads) HCF-1PRO repeats are
indicated. (C and D) Ribbon diagrams of the front (C) and left-side (D) views of the VP16 core (27). The diagram is colored red, green, blue, and
yellow from the amino terminus to the carboxy terminus. Disordered regions are represented by the broken lines (adapted from reference 27). The
bottom, back, and headrest of the seat-like structure are identified in panel D.
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main, however, protected nucleotides over the entire octamer
sequence from DNase I digestion but failed to protect nucle-
otides in the D element (compare lanes 1 and 9). Addition of
all three minimal-region proteins together, however, resulted
in the same extended protection of the TAATGARAT and D
element sequences as elicited by the VP16-induced complex
assembled with full-length proteins (compare Fig. 3A, lane 4,
with Fig. 3B, lane 8). These results show that regions in HCF-1,
Oct-1, and VP16 dispensable for VP16-induced complex for-
mation are not responsible for the extended TAATGARAT-D
element VP16-induced complex footprint. There may be an
effect of the full-length proteins (e.g., Oct-1) over the octamer
sequence, because the ATGC position of the octamer se-
quence was not as well protected from digestion with the min-
imal complex as with the native complex (compare Fig. 3A,
lane 4, and B, lane 8). We conclude, however, that to a large
degree, in a native VP16-induced complex, the regions of
HCF-1, Oct-1, and VP16 that are not essential for VP16-
induced complex formation are probably not associated with
the DNA in any specific and stable manner.
VP16 is responsible for the extended VP16-induced complex
footprint. In the aforementioned studies, HCF-1 and VP16,
when added together, generated the extension of the TAAT
GARAT protection pattern. To determine whether it is the
HCF-1 or VP16 protein alone or in combination that is re-
sponsible for the extended DNase I protection pattern, we
investigated whether, in the absence of HCF-1N380, VP1649–412
can extend the Oct-1 POU domain DNase I protection pattern.
To accomplish this, we added high concentrations of VP16 to
overcome the lack of HCF-1 stabilization. Figure 4 shows the
FIG. 2. A VP16-induced complex can be assembled with proteins
synthesized in E. coli. (A) Electrophoretic mobility retardation assay of
a VP16-induced complex assembled from full-length proteins. All sam-
ples contain the (OCTA1)TAATGARAT probe either alone (lane 1)
or incubated with HeLa cell nuclear extract (Nuc. Ext.; lanes 3 and 4)
or full-length VP16 (lanes 2 and 4), as indicated above each lane. (B)
Electrophoretic mobility retardation assay of a VP16-induced complex
assembled from recombinant proteins synthesized in E. coli represent-
ing the minimal domains sufficient for VP16-induced complex forma-
tion. All samples contain the (OCTA1)TAATGARAT probe either
alone (lane 1) or with HCF-1N380 (lanes 2, 4, 6, and 8). VP1649–412
(lanes 3, 4, 7, and 8), or the Oct-1 POU domain (lanes 5 to 8), as
indicated above the lanes. The positions of the free (OCTA1)TAAT
GARAT probe (Free Probe), the Oct-1–DNA complex (Oct-1), the
Oct-1 POU domain–DNA complex (Oct-1 POU), the VP16-induced
complex (VIC), and the VP16-induced complex with minimal domains
(Mini-VIC) are shown at the left.
FIG. 3. A VP16-induced complex assembled from full-length pro-
teins and one assembled from the minimal domains sufficient for
VP16-induced complex formation show similar DNase I protection
patterns. (A) DNase I protection analysis of a VP16-induced complex
assembled from full-length proteins. All samples contain the (OCTA1)
TAATGARAT probe incubated either alone (lane 1) or with HeLa
cell nuclear extract (Nuc. Ext.; lanes 3 and 4) or full-length VP16
(lanes 2 and 4), as indicated above each lane. The same amount of
DNase I was used in each sample, resulting in decreased nuclease
activity in the samples containing nuclear extract (lanes 3 and 4). (B)
DNase I protection analysis of a VP16-induced complex assembled
from recombinant proteins representing the minimal domains suffi-
cient for VP16-induced complex formation. All samples contain the
(OCTA1)TAATGARAT probe incubated either alone (lane 1) or
with HCF-1N380 (lanes 2, 4, 6, and 8), VP1649–412 (lanes 3, 4, 7, and 8),
or the Oct-1 POU domain (lanes 5 to 8), as indicated above each lane.
Lane 9 contains 10 times the amount of the Oct-1 POU domain as lane
5. The positions of the octamer (OCTA), TAATGARAT (TAAT),
and D (D) elements as determined by chemical sequencing of the same
probe, are indicated at the left. The identities of the sites of DNase I
cleavage are indicated by the sequence and brackets to the far left. The
boundaries of the regions protected from DNase I digestion by Oct-1,
Oct-1 POU, the VP16-induced complex (VIC), and the minimal VP16-
induced complex (Mini-VIC) are indicated to the right.
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results of this experiment. As expected, high concentrations of
the Oct-1 POU domain protected the octamer sequence but
not the D element sequence (compare lanes 1 and 2), and with
lower concentrations of the Oct-1 POU domain (lanes 3 and
8), the presence of VP1649–412 and HCF-1N380 produced the
extended VP16-induced complex footprint over the D element
sequence and beyond (lane 4). Consistent with its role in sta-
bilizing the VP16-induced complex, removal of HCF-1 (lane 5)
resulted in a general decrease in the overall protection pattern
(compare lanes 3 to 5). At these concentrations of the Oct-1
POU domain and VP16, however, an extended VP16-induced
complex protection pattern (mini-VIC) is evident (compare
lanes 3 and 5), and increasing concentrations of VP16 en-
hanced the D element protection pattern (compare lanes 7 and
8) without decreasing the protection pattern over the octamer
sequence. Thus, in the absence of HCF-1, the Oct-1 POU
domain and the VP16 core (lane 7), but not the Oct-POU
domain alone (lane 2), are sufficient to protect the entire ICP0
TAATGARAT site. These results suggest that it is VP16 that
is directly responsible for the protection of 39 residues flanking
the DNA-bound Oct-1 POU domain, consistent with previous
models of the VP16-induced complex (6, 13, 20, 27, 32, 43).
VP16 mutagenesis. To explore how VP16 coordinates as-
sembly of the VP16-induced complex, we used the structure of
the VP16 core as a guide for a mutational analysis of its
surface. The structure of the VP16 core, as shown in Fig. 1C
and D, has been likened to a seat, possessing a back, a bottom,
and a headrest (27; Fig. 1D). The seat back is formed by two
long, antiparallel a helices (shown in green) forming a coiled-
coil structure that runs the length of the protein. The seat
bottom projects out from the two long a helices. The seat back
and bottom form a concave surface which has been proposed
by molecular modeling to be involved in DNA binding (27).
The position of the unstructured regions of the VP16 core is
indicated by the dashed lines. In an earlier mutational analysis
of VP16 (25), we showed that the major unstructured region of
the VP16 core is involved in DNA binding, as well as associ-
ation with Oct-1 and HCF-1. To identify residues in the or-
dered region of the VP16 core that are involved in DNA
binding, we selected many of the basic amino acids across its
surface for replacement with alanine because, within DNA-
binding proteins, basic residues are often critical for binding to
DNA.
We tested these substitution mutant proteins in four sepa-
rate in vitro assays: (i) VP16-induced complex formation; (ii)
VP16 binding to HCF-1; (iii) VP16 binding to Oct-1 and DNA
in the absence of HCF-1; and (iv) VP16 binding to DNA on its
own. Table 1 lists all of the point mutations that were tested
and summarizes their effects in each of the four VP16 activity
assays. Two mutations of the surface of the VP16 core, R331A
and R341A, have been described and characterized in similar
assays previously (25); the results for these two mutant pro-
teins from that study are included in Table 1 for comparison.
In the activity assays performed here, we included three pre-
viously characterized mutations of the disordered VP16 core
region that have been shown to selectively prevent VP16 bind-
ing to HCF-1 (E361A/385Ala3), DNA (366Ala3), and an Oct-
1–DNA complex (G374A) (25). Described below are the ac-
tivities of a representative set of six mutant proteins (R64A,
R100A, R214A, R221A, R236A, and R290A) in each of the
four activity assays. All of the mutant proteins lacked the
carboxy-terminal transcriptional activation domain (VP16DC)
and were synthesized in E. coli as fusions to GST.
Some, but not all, basic residues on the surface of the VP16
core are important for VP16-induced complex formation. Fig-
ure 5 shows the abilities of the selected mutant proteins to
support VP16-induced complex formation. As expected, addi-
tion of the Oct-1 POU domain and HCF-1N380 generated an
Oct-1 POU domain–DNA complex alone (lane 2; labeled
Oct-1 POU) and further addition of wild-type VP16 protein
produced a slower-migrating VP16-induced complex (lane 3;
labeled VIC). As expected (25), the three previously charac-
terized mutant proteins (E361A/385Ala3, 366Ala3, and
G374A) failed to support VP16-induced complex formation
(lanes 10 to 12). Owing to the increased ability of the HCF-1
association-defective E361A/385Ala3 mutant protein to asso-
ciate with DNA in the absence of HCF-1, as observed previ-
ously (25), it formed a weak, faster-migrating VP16-induced
FIG. 4. The VP16 core is sufficient to extend the DNase I protec-
tion pattern generated by the Oct-1 POU domain. DNase I protection
analysis of Oct-1 POU domain–VP16 core complexes on an (OCTA1)
TAATGARAT-containing probe. The Oct-1 POU domain was as-
sayed at either a low (lanes 3 to 8) or a high (10X; lane 2) concentra-
tion along with VP1649–412 (lanes 4 to 7) either in the absence (lanes 1
to 3 and 5 to 8), or in the presence (lane 4) of HCF-1N380. As indicated,
lanes 6 and 7 contain two- or threefold more VP1649–412 protein,
respectively, than lanes 4 and 5. The positions of the DNA sites and
DNase I protection patterns are as described in the legend to Fig. 3.
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complex that probably lacks HCF-1 (asterisk in Fig. 5). Of the
representative set of mutations, only one prevented VP16-
induced complex formation entirely (R214A; lane 6); another
had an intermediate effect (R221A; lane 7). The remaining
selected proteins behaved similarly to wild-type VP16. As
shown in Table 1, alanine substitutions for residues 217, 224,
and 331 (see reference 25) also prevented VP16-induced com-
plex assembly whereas replacement of residues 184 and 341
(see reference 25) had partial effects on complex assembly.
These results suggest that some, but not all, basic amino acids
on the surface of the VP16 core are involved in VP16-induced
complex formation.
The basic-residue substitutions do not affect HCF-1 associ-
ation. To examine how VP16 association with HCF-1 might be
affected by the VP16 core surface mutations, we used a coim-
munoprecipitation assay based on the ability of VP16 to bind
HCF-1 in the absence of DNA (47). HCF-1N380 was tagged at
its amino terminus with an HA epitope (HA–HCF-1N380) and
both HA–HCF-1N380 and VP16 were produced by in vitro
translation. Figure 6 shows the effects of the selected set of
mutations on HCF-1N380 association. The lower panel shows
20% of the input VP16 protein, and the upper panel shows the
complexes that were recovered after immunoprecipitation of
HA–HCF-1. As expected, the HCF-1 association-defective
E361A/385Ala3 VP16 mutant protein was not recovered in this
assay (lane 9). All of the remaining mutant proteins were
capable of associating with HCF-1N380, most at or near the
wild-type level (lanes 3 to 8 and 10 and 11; Table 1). These
results show that replacement of many basic amino acids in the
structured portion of the VP16 core with alanine does not
prevent VP16 association with HCF-1.
Some basic-residue substitutions resulting in competence
for VP16-induced complex formation cause a defect in DNA
binding by VP16 on its own or with the Oct-1 POU domain. We
next tested the effects of the mutations on VP16 binding to
DNA either alone or in the presence of Oct-1. As shown in Fig.
7A, addition of an amount of VP16 eightfold greater than that
required for VP16-induced complex formation (i.e., 200 ng), in
the presence of the Oct-1 POU domain, stimulates the forma-
tion of an HCF-1-independent VP16–Oct-1 POU domain–
DNA complex (37; compare lanes 2 and 3, labeled VP16 1
Oct-1 POU). As expected (25), the mutation 366Ala3 and
G374A, which disrupt interaction with the DNA and the Oct-1
POU domain, respectively, prevented the formation of the
VP16–Oct-1 POU complex (lanes 11 and 12), whereas the
E361A/385Ala3 mutation (lane 10) resulted in cooperative
binding with the Oct-1 POU domain and DNA with increased
affinity (a slightly faster-migrating complex [asterisk] is proba-
bly owing to E361A/385Ala3 VP16 bound to DNA alone).
From the selected set of VP16 core mutations, R214A, which
prevented the formation of a VP16-induced complex, also pre-
vented binding to the Oct-1 POU domain–DNA complex (lane
6). The substitution mutation R217A, R224A, and R331A (see
reference 25) behaved similarly (Table 1). Two additional se-
TABLE 1. Activities associated with VP16 proteins containing amino acid substitutions in the core domaina
VP16 protein VP16-inducedcomplex formation
Interaction with: Relative in vivo
activityd Color
e
HCF-1 DNA Oct-1–DNA
Wild type 11 11 11 11 1 Blue
Substitutions
R64A 11 11 2 2 0.64 Yellow
R100A 11 11 1 11 0.87 Blue
K103A 11 11 1 11 ND Blue
R129A 11 11 1 11 ND Blue
R143A 11 11 11 11 ND Blue
R155A 11 11 11 11 ND Blue
R184A 1 11 2 2 ND Yellow
R208A 11 11 6 1 ND Blue
R214A 2 11 2 2 0.01 Red
R217A 2 11 2 2 ND Red
R221A 1 11 2 2 0.05 Yellow
R224A 2 11 2 2 ND Red
R236A 11 11 6 1 1.07 Blue
R290A 11 11 11 11 1.04 Blue
R331Ab 2 11 2 2 ND Red
R341Ab 1 11 2 1 ND Yellow
E361A/385Ala3c 2 2 111 111 0.02
366Ala3c 2 11 2 2 ,0.01
G374A 2 11 11 2 0.01
Deletions
D198-201 2 11 2 2 ND
D187-206 2 1 2 2 ND
a Wild-type activity is set at 11 for each assay. 111, more active than wild-type VP16; 1, less active than wild-type VP16; 6, barely detectable activity; 2
undetectable activity.
b Results from Lai and Herr (25).
c E361/385Ala3 contains alanine substitutions at residues E361, D385, D386, and D387, and 366Ala3 contains alanine substitutions at residues R366, R368, and K370.
d The results shown are averages of two independent experiments and are within 620%. ND; not done.
e Color of residue in Fig. 10.
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lected mutations, however, R64A and R221A, which were able
to support VP16-induced complex formation, albeit to various
degrees, also prevented binding to the Oct-1 POU domain–
DNA complex (lanes 4 and 7). The R184A substitution muta-
tion produced a similar phenotype (Table 1). The remainder of
the substitution mutant proteins could still cooperate for bind-
ing of the Oct-1 POU domain–DNA complex, although on
occasion with reduced affinity (e.g., R236A, lanes 5, 8, and 9
and Table 1).
Figure 7B shows the results of assaying the ability of the
VP16 mutant proteins to bind DNA on their own. An amount
of VP16 fivefold greater than that used in the Oct-1 POU
domain–DNA complex-binding assay (i.e., 1 mg) bound to the
probe nonspecifically under these conditions (37; lanes 2 and
12, labeled VP16). As previously reported, the G374A mutant
protein (lane 11) bound DNA similarly to wild-type VP16,
whereas the E361A/385Ala3 mutant protein bound DNA with
increased affinity (compare lanes 9 and 2) and the 366Ala3
mutant protein failed to bind DNA on its own (lane 10). Of the
representative set of mutant proteins, R64A, R214A, and
R221A (lanes 3, 5, and 6) failed to bind DNA on their own and
mutant proteins R184A, R217A, R224A, R331A, and R341A
(see reference 25) behaved similarly (Table 1). The remaining
mutant proteins, R100A, R236A, and R290A (lanes 4, 7, and 8;
Table 1), bound with various reduced affinities (weak but de-
tectable binding by R236A is evident on longer exposure of the
same gel; data not shown). These results suggest that the in-
ability of mutant proteins R64A and R221A to interact coop-
eratively with the Oct-1 POU domain and DNA (Fig. 7A) is
due to their reduced ability to bind DNA on their own. The
ability of these VP16 mutant proteins to form a complete
VP16-induced complex but not subcomplexes lacking HCF-1
suggests that HCF-1 is able to suppress the defects of some of
the VP16 point mutant proteins for interaction with DNA or
Oct-1. These results contrast with those of mutations in the
disordered region of the VP16 core, where DNA- protein or
Oct-1-binding defects were not overcome by HCF-1 (25). Four
of the substitution mutant proteins, however, did display loss of
both DNA binding alone and VP16-induced complex forma-
tion, as in the case of the disordered region mutations (25). We
suggest below that the residues affected in these mutant pro-
teins, R214, R217, R224, and R331, form the TAATGARAT-
binding surface on the concave portion of the VP16 seat.
Deletions within the VP16 headrest prevent VP16 binding to
DNA. Amino acid sequence alignment of VP16 core domains
from HSV-1, BHV-1, varicella-zoster virus, gallus herpesvirus
type 1, and equine herpesvirus type 1 VP16 orthologs shows
sequence similarity scattered throughout the VP16 core (27).
One interesting feature, however, of the HSV-1 VP16 struc-
ture, the headrest (Fig. 1D), displays little, if any, amino acid
sequence similarity. The HSV-1 VP16 headrest, at 27 amino
acids (residues 187 to 213), is the longest nonconserved region
of the VP16 core. Indeed, the equine herpesvirus type 1 and
BHV-1 VP16 proteins even contain small three- and four-
amino-acid deletions, respectively, in this region (see reference
27). Although the headrest is not conserved, it is flanked by
basic residues important for VP16-induced complex formation
and DNA binding (e.g., R184, R214, and R217; Table 1).
Therefore, we examined, by deletion mutagenesis, whether this
variable region is important for VP16-induced complex forma-
tion, particularly DNA binding.
We created two deletions: a small deletion, called D198–201,
FIG. 5. Some basic amino acids in the structured VP16 core are
important for VP16-induced complex formation. An electrophoretic
mobility retardation assay for VP16-induced complex formation of a
representative set of alanine mutations in the VP16 core was per-
formed. An (OCTA1)TAATGARAT-containing DNA probe was in-
cubated in the absence (lane 1) or presence of the Oct-1 POU domain
and HCF-1N380 (lanes 2 to 13) along with either wild-type (WT; lanes
3 and 13) or mutant VP16 protein (lanes 4 to 12), whose identity is
indicated above each lane. The positions of the free (OCTA1)TAAT
GARAT probe (Free Probe), the Oct-1 POU domain–DNA complex
(Oct-1 POU), and the VP16-induced complex (VIC) are shown at the
left. The asterisk indicates a likely HCF-1-independent VP16-induced
complex (lane 10; see reference 25).
FIG. 6. Basic amino acid substitutions in the structured VP16 core
do not prevent association with HCF-1. Coimmunoprecipitation of
VP16 core mutants protein with HA epitope-tagged HCF-1. HCF-
1N380 and the wild-type (WT) and mutant VP16 proteins were trans-
lated in vitro and labeled with [35S]methionine as described in
Materials and Methods. HCF-1N380 was incubated with either unpro-
grammed lysate (lane 1) or wild-type (lanes 2 and 12) or mutant (lanes
3 to 11) VP16 protein, as indicated above each lane. Immune com-
plexes were recovered by immunoprecipitation with an anti-HA mono-
clonal antibody (top; aHA IP), resolved by SDS–8% PAGE, and
detected by fluorography. The lower blot shows 20% of the VP16
starting material (20% VP16 Load). The mobility of VP16 and HA
epitope-tagged HCF-1N380 is indicated at the left.
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which mimics the four-amino-acid BHV-1 VP16 ortholog de-
letion, and a more radical deletion, called D187–206, which
removes most of the headrest region. Both of the resulting
mutant proteins were defective for VP16-induced complex for-
mation (Fig. 8A), Oct-1 POU domain–DNA complex binding
(Fig. 8B), and DNA binding on their own (Fig. 8C) but were
active for HCF-1 association (Fig. 8D), although the D187–206
mutant, which is difficult to see owing to its faster electro-
phoretic migration, is partially defective for HCF-1 association
(lane 4 and data not shown). These results show that even
headrest sequences which have no apparent counterpart in a
VP16 ortholog—the BHV-1 VP16 protein—are important ei-
ther directly or indirectly (e.g., for structural stability) for VP16
binding to DNA.
VP16 mutant proteins defective for VP16-induced complex
formation in vitro are defective for transcriptional activation
in vivo. To determine the effects of the selected set of mutant
VP16 proteins on transcriptional activation in vivo, we assayed
their abilities to activate transcription in human cells. Figure 9
shows the results of VP16-dependent transcriptional activation
of a b-globin promoter containing multiple tandem TAATGA
RAT sites after transient expression of wild-type and mutant
VP16 proteins in HeLa cells. As expected, expression of wild-
type VP16 strongly activated the reporter (compare lanes 1
and 2) and the E361A/385Ala3, 366Ala3, and G374A VP16
mutant proteins (lanes 9 to 11), which failed to form a VP16-
induced complex, failed to stimulate transcriptional activity
from the reporter (25). Similar to wild-type VP16, the R64A,
R100A, R236A, and R290A VP16 mutant proteins stimulated
transcription of the reporter to nearly wild-type levels (lanes 3,
4, 7, and 8; Table 1). In contrast, R214A, which failed to form
a VP16-induced complex in vitro, failed to stimulate reporter
gene expression in vivo (lanes 5; Table 1) and the R221A
mutant, which showed reduced levels of VP16-induced com-
plex formation in vitro, displayed weak but detectable levels of
transcriptional activity in vivo (lane 6; Table 1). Therefore, the
abilities of the selected set of mutant VP16 proteins to stimu-
late transcription in vivo closely parallel their abilities to form
a VP16-induced complex in vitro.
DNA-binding mutations in VP16 map to the concave surface
formed by the seat bottom and back of the VP16 core struc-
ture. Figure 10 summarizes the activities of the structured
VP16 core region alanine substitution mutant proteins with
three representations of the free form of the structured VP16
core. Included are the two previously characterized mutant
proteins, R331A and R341A, which prevent VP16 DNA bind-
ing (Table 1) (25). The structured VP16 core is shown as a
molecular surface representation (30) in white, with residues
whose replacement with alanine prevents both VP16-induced
complex formation and VP16 DNA binding shown in red those
whose replacement with alanine prevents DNA binding but
whose inactivity can be suppressed by HCF-1 shown in yellow,
and those whose replacement with alanine has no evident
effect shown in blue. Figure 10B shows the same projection of
the VP16 core as in Fig. 1C.
The basic-residue substitutions whose DNA-binding defects
FIG. 7. Multiple basic amino acids in the structured VP16 core are important for DNA binding. (A) Cooperative VP16 binding to the Oct-1
POU domain–DNA complex. The (OCTA1)TAATGARAT probe was incubated either in the absence (lane 1) or in the presence (lanes 2 to 13)
of the Oct-1 POU domain and wild-type (WT; lanes 3 and 13) or mutant (lanes 4 to 12) VP16, whose identity is indicated above each lane. (B)
VP16 binding to DNA alone at high concentrations of VP16. The (OCTA1)TAATGARAT probe was incubated either in the absence (lane 1)
or in the presence of wild-type (lanes 2 and 12) or mutant (lanes 3 to 11) VP16, whose identity is indicated above each lane. Complexes were
resolved on a 6% gel as described in Materials and Methods. The positions of the free (OCTA1)TAATGARAT probe (Free Probe) and the Oct-1
POU domain–DNA (Oct-1 POU), VP16-DNA (VP16), and VP16–Oct-1 POU domain–DNA (VP16 1 Oct-1 POU) complexes are shown at the
left. The asterisk indicates a likely complex of VP16-DNA alone (lane 10; see reference 25).
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are suppressed by HCF-1 (yellow residues) form a ring around
the VP16 protein. We do not know the reason for the HCF-
1-suppressible phenotype of these mutant proteins, although it
could reflect destabilization of a critical and sensitive region of
the VP16 structure by the mutations. The basic residues that
when replaced with alanine affect DNA binding by VP16 in the
presence or absence of HCF-1 and Oct-1 all lie in close prox-
imity on the concave part of the seat-like structure. This pu-
tative DNA-binding surface is most clearly visible when viewed
from either side (Fig. 10A and C). We know of no known
DNA-binding structure that resembles that identified here in
VP16. Comparison of the VP16 core structure with other
known protein structures by using the DALI server (15; http:
//www.ebi.ac.uk/dali/) did not reveal extensive similarity to any
known DNA-binding protein structures. This result is consis-
tent with the hypothesis that VP16 binds DNA through a novel
DNA-binding structure.
DISCUSSION
We have described the role of VP16 in DNA recognition of
its cis-regulatory site, the TAATGARAT element. We have
shown that a VP16-induced complex can be assembled from
recombinant proteins synthesized in E. coli that represent min-
imal regions necessary for VP16-induced complex formation.
By using these minimal regions, we have shown that VP16 is
sufficient to extend the DNase I protection pattern of the Oct-1
POU domain alone, positioning VP16 over the D element. In
addition, we have defined a surface on the concave side of the
VP16 core that is involved in DNA binding. These results
suggest that VP16 directly recognizes its cis-regulatory site, the
TAATGARAT element, by using a novel DNA-binding struc-
ture.
VP16-induced complex formation in the absence of eukary-
otic cell-specific modification. The ability to assemble effi-
ciently a VP16-induced complex with recombinant proteins
synthesized in E. coli suggests that eukaryotic cell-specific post-
FIG. 8. The VP16 core headrest is important for DNA binding. Wild-type (WT) and mutant (D198–201 and D187–206) VP16 molecules were
tested for VP16-induced complex formation (A) and for cooperative binding to the Oct-1 POU domain–DNA complex (B), DNA alone (C), and
HCF-1 (D). (A) VP16-induced complex formation was assayed as described in the legend to Fig. 5. The presence or absence of wild-type or mutant
VP16 along with the Oct-1 POU domain and HCF-1N380 is indicated above each lane. (B) The ability of VP16 to interact cooperatively with the
Oct-1 POU domain was assayed as described in the legend to Fig. 7A. The presence or absence of wild-type or mutant VP16 and the Oct-1 POU
domain is indicated above each lane. (C) The binding of VP16 alone to DNA was assayed as described in the legend to Fig. 7B. The presence or
absence of wild-type or mutant VP16 is indicated above each lane. (D) VP16 binding to HCF-1 was assayed as described in the legend to Fig. 6.
The presence or absence of wild-type or mutant VP16 and HA epitope-tagged HCF-1N380 is indicated above each lane. The black dots indicate
the position of the recovered VP16 proteins. The positions of the different electrophoretic species are as described in the Fig. 5 to 7 legends.
FIG. 9. In vivo transcriptional activation by selected amino acid
substitutions in the VP16 core. A b-globin (OCTA1)TAATGARAT-
containing reporter plasmid and an a-globin internal reference plas-
mid were transfected into HeLa cells in the absence (lane 1) or pres-
ence of wild-type (WT; lanes 2 and 12) or mutant (lanes 3 to 11) VP16
expression plasmids. RNA was collected 48 h after transfection and
analyzed by RNase protection assay as described in Materials and
Methods. The positions of correctly initiated a-globin (a), b-globin
(b), and b-globin readthrough (RT) transcripts are indicated at the
left.
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translational modifications, such as protein phosphorylation,
are not required for VP16-induced complex assembly. These
results do not support previous suggestions that either VP16
(33) or HCF-1 (21) needs to be modified to support VP16-
induced complex formation. In the studies described here, we
used the minimal region of each protein synthesized in E. coli
to assemble an unmodified complex. It is therefore possible
that full-length proteins possess inhibitory regions that need to
be inactivated by posttranslational modification to permit as-
sembly of the VP16-induced complex. Elsewhere, however, we
have shown that dephosphorylation of native full-length hu-
man HCF-1 does not affect its ability to stabilize a VP16-
induced complex (49a). We conclude that posttranslational
modifications are most likely not required for VP16-induced
complex formation.
Previous attempts to form a VP16-induced complex with
proteins synthesized in E. coli (see references 23 and 33) may
have failed owing to the difficulty of producing active HCF-1 in
E. coli. The HCF-1 VP16-interaction domain is predicted to
form a six-bladed b propeller structure (47) similar to those
formed by WD40 repeat-containing proteins such as the b
subunit of heterotrimeric G proteins (26, 36, 46). Studies by
Garcia-Higuera and colleagues (7) have shown that it is often
difficult to synthesize properly folded WD40 repeat-containing
proteins. For example, after synthesis in E. coli, the G protein
b subunit fails to fold properly; instead, it requires synthesis in
a eukaryotic system in the presence of the g subunit for proper
folding. Therefore, b propeller structures may be inherently
difficult to fold into active proteins. By synthesizing the His-
tagged HCF-1N380 protein described here in E. coli grown at a
low temperature (i.e., 18°C), we may have promoted proper
folding of the HCF-1N380 protein by slowing its rate of synthe-
sis.
VP16 is responsible for the extended VP16-induced complex
footprint. Results from the DNase I protection experiments
showed that the Oct-1 POU domain with high concentrations
of the VP16 core protein in the absence of HCF-1 can generate
a protection pattern similar to that obtained with a complete
VP16-induced complex assembled with full-length proteins
(Fig. 3 and 4). This result shows that VP16 is sufficient to
extend the Oct-1 footprint. Walker and colleagues (45) failed
to see such an extended footprint in the presence of VP16 and
the Oct-1 POU domain alone and speculated that HCF-1 is
responsible for the footprint extension. One possible explana-
tion for the failure of Walker and colleagues to observe an
effect of VP16 on the Oct-1 protection pattern in the absence
of HCF-1 (45) is that, in those studies, the DNA cleavage
reactions were performed not in solution at equilibrium as
described here but, instead, on protein-DNA complexes in
polyacrylamide gels after electrophoretic separation. Perhaps
the fractionated complexes dissociate prior to or during post-
electrophoresis chemical treatment. A second difference is the
use of the VP16 core in this study, as opposed to the use of
full-length VP16 with its acidic transcriptional activation do-
FIG. 10. Mutations that disrupt DNA binding map to the concave surface of the structured VP16 core. A molecular surface representation (30)
was used to generate three projections of the VP16 core. The surface of the VP16 core is shown in white. The surfaces of amino acids whose
replacement with alanine prevents DNA binding and VP16-induced complex formation are shown in red, those whose replacement prevents DNA
binding but not full VP16-induced complex formation are shown in yellow, and those whose replacement results in wild-type (WT) or nearly
wild-type VP16 activity are shown in blue. A, right-side view; B, front view; C, left-side view.
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main by Walker et al. (45), which may destabilize the VP16–
Oct-1 complex (see reference 23). Whichever the case, the
results presented here clearly demonstrate that, in the absence
of HCF-1 but in combination with the Oct-1 POU domain,
VP16 can reproduce the complete DNase I protection pattern
of a complete VP16-induced complex, indicating that VP16
does, indeed, contact the DNA.
The conclusion that VP16 contacts DNA is consistent with
other findings; including those of the abilities (i) of VP16 to
cross-link to DNA (20), (ii) of VP16 to bind DNA on its own
(20, 37), and (iii) of VP16 orthologs to discriminate among
different TAATGARAT elements (16, 29). Although VP16
can bind DNA on its own at high concentration, this binding
displays little, if any, sequence specificity (37, 45). Thus, asso-
ciation with Oct-1 apparently enhances the sequence-specific
DNA binding of VP16, perhaps by stabilizing a structure of
VP16 that has increased sequence-specific DNA recognition
properties and/or by recruiting VP16 to a particular site on the
DNA, thus limiting its freedom to bind to other, nonspecific
DNA sequences.
Amino acids in the VP16 core responsible for DNA binding
are conserved among VP16 orthologs. To identify residues on
the surface of VP16 involved in DNA binding, we chose to
replace solvent-exposed basic amino acids because basic resi-
dues are frequently involved in DNA binding and sequence
recognition. Several amino acids involved in DNA binding
were identified, and these and a previously identified residue
(25) all map on the concave surface of the seat-like VP16
structure (red residues in Fig. 10). Interestingly, the amino
acids likely to be directly involved in DNA binding (i.e., R214,
R217, R224, and R331) are either universally conserved or, as
in one case (R224), always basic residues (i.e., arginine or
lysine) among VP16 orthologs, suggesting that these residues
define a conserved DNA-binding surface on VP16. Indeed, two
of these conserved residues (R214 and R217) are located in the
most highly conserved segment of the VP16 core (residues 214
to 218).
Several VP16 mutant proteins (R64A, R184A, R221A, and
R341A; the positions colored yellow in Fig. 10) were unable to
bind DNA on their own but could still support wild-type or
nearly wild-type levels of VP16-induced complex formation.
Thus, HCF-1 is able to suppress the defects of some mutant
proteins. Examination of the positions of the mutations on the
surface of VP16 suggests that they are not located at random
but, instead, are clustered near and around the putative DNA-
binding surface (Fig. 10). One explanation for the ability of
HCF-1 to stabilize these mutations is that they affect the con-
formation of VP16, and HCF-1 is able to stabilize the active
conformation of VP16. Whatever the case, the ability of
HCF-1 to suppress defects shown by this class of mutant pro-
teins is not particular to the in vitro assay conditions because
mutant proteins of this class could activate transcription in
vivo, albeit to differing extents (Fig. 9 and Table 1).
Mutations disrupting the VP16 headrest showed that it also
plays a role in VP16-induced complex formation and DNA
binding. However, in contrast to other DNA-binding residues,
the headrest shows little sequence conservation among VP16
orthologs. An attractive possibility is that the headrest recog-
nizes the D element and is responsible for determining the
DNA-binding specificity of VP16 orthologs. The VP16 head-
rest neighbors amino acids (e.g., R214) that are conserved
among VP16 orthologs and are important for DNA binding.
Perhaps the sequence variability of the headrest allows it to
provide the specificity needed to recognize differentially the D
element. In support of this possibility, we have observed that
exchanging the HSV-1 headrest (amino acids 186 to 213) with
the corresponding amino acids from BHV-1 VP16 resulted in
a chimeric HSV-1–BHV-1 protein that could recognize a
BHV-1 TAATGARAT element better than an HSV-1 TAAT
GARAT element, although the overall DNA-binding activity
was very low (R. Babb and W. Herr, unpublished results).
Does VP16 possess a bipartite DNA-binding domain? The
previous study of Lai and Herr (25) showed that residues
within the unstructured region of the VP16 core are involved in
DNA binding, and the results reported here identify a surface
of the structured region of VP16 that is involved in DNA
binding. These findings suggest a possible bipartite VP16
DNA-binding structure, in which both the structured and un-
structured regions of VP16 may contact separate sequences in
the TAATGARAT element. For example, the structured re-
gion may contact the D element, consistent with its role in
discriminating the D element sequence (27), and the unstruc-
tured region may adopt a structure upon its association with
the Oct-1 POU homeodomain and bind the GARAT sequence
abutting the TAAT POU homeodomain binding site. If this is
true, then both of the DNA-binding components of the VP16-
induced complex, the Oct-1 POU domain and VP16, contain
bipartite DNA-binding structures. Such structures may be ad-
vantageous because they permit flexibility in protein-DNA in-
teraction and greater combinatorial complexity.
A novel DNA-binding structure. Cognizant that VP16 can
recognize the TAATGARAT D element sequence (16, 27, 29)
and that at least one residue on the concave surface of VP16 is
involved in DNA binding (R331; 25), Liu et al. (27) proposed
a model of VP16 bound to a TAATGARAT element with the
Oct-1 POU domain. In that model, the TAATGARAT D
element rests on the bottom and back of the VP16 seat, with
the disordered VP16 segment positioned for association with
the Oct-1 POU homeodomain. The results presented here are
consistent with this model because the basic residues that play
a role in DNA binding (R214, R217, R224, and R331) are all
in close apposition to the DNA in the model. Three of these
residues—R214, R217, and R224—are all on one face of an a
helix, the second of the two long a helices that make up the
back of the seat, that, in the model, crosses the major groove
of the DNA. Thus, by using a mechanism common to many
DNA-binding proteins, VP16 may recognize the DNA by po-
sitioning an a helix within the major groove of the DNA. A
more precise model for VP16 binding to DNA, however, re-
quires a high-resolution structure of VP16 bound to DNA and
the Oct-1 POU domain. Nevertheless, the studies presented
here reveal mechanisms whereby a transcription factor that
displays no inherent DNA-binding specificity on its own can
interpret signals in the DNA to assemble a transcriptional
regulatory complex—in this instance, the VP16-induced complex.
ACKNOWLEDGMENTS
We thank X. Cheng for discussions; A. Bubulya for help with the in
vivo transcriptional activation studies; C. Sanders for advice on chem-
ical DNA sequencing; L. Joshua-Tor and M. Wang for help with the
VOL. 21, 2001 VP16 DNA-BINDING SURFACE 4711
 o
n
 January 22, 2014 by M
AIN LIBRARY
http://m
cb.asm
.org/
D
ow
nloaded from
 
VP16 structural similarity analysis; X. Zhao for HeLa cell nuclear
extract; N. Hernandez, L. Joshua-Tor, A. Stenlund, and J. Wysocka for
comments on the manuscript; J. Duffy and P. Renna for artwork; and
J. Reader for help with manuscript preparation.
These studies were funded by U.S. Public Health Service grant
CA-13106 from the National Cancer Institute.
REFERENCES
1. apRhys, C. M. J., D. M. Ciufo, E. A. O’Neill, T. J. Kelly, and G. S. Hayward.
1989. Overlapping octamer and TAATGARAT motifs in the VF65-response
elements in herpes simplex virus immediate-early promoters represent inde-
pendent binding sites for cellular nuclear factor III. J. Virol. 63:2798–2812.
2. Cleary, M. A., S. Stern, M. Tanaka, and W. Herr. 1993. Differential positive
control by Oct-1 and Oct-2: activation of a transcriptionally silent motif
through Oct-1 and VP16 corecruitment. Genes Dev. 7:72–83.
3. Cleary, M. A., and W. Herr. 1995. Mechanisms for flexibility in DNA se-
quence recognition and VP16-induced complex formation by the Oct-1 POU
domain. Mol. Cell. Biol. 15:2090–2100.
4. Cleary, M. A., P. S. Pendergrast, and W. Herr. 1997. Structural flexibility in
transcription complex formation revealed by protein-DNA photocrosslink-
ing. Proc. Natl. Acad. Sci. USA 94:8450–8455.
5. Cousens, D. J., R. Greaves, C. R. Goding, and P. O’Hare. 1989. The C-
terminal 79 amino acids of the herpes simplex virus regulatory protein,
Vmw65, efficiently activate transcription in yeast and mammalian cells in
chimeric DNA-binding proteins. EMBO J. 8:2337–2342.
6. Douville, P., M. Hagmann, O. Georgiev, and W. Schaffner. 1995. Positive and
negative regulation at the herpes simplex virus ICP4 and ICP0 TAATGA
RAT motifs. Virology 207:107–116.
7. Garcia-Higuera, I., J. Fenogolia, Y. Li, C. Lewis, M. P. Panchenko, O.
Reiner, T. F. Smith, and E. J. Neer. 1996. Folding of proteins with WD-
repeats: comparison of six members of the WD-repeat superfamily to the G
protein b subunit. Biochemistry 35:13985–13994.
8. Gerster, T., and R. G. Roeder. 1988. A herpesvirus trans-activating protein
interacts with transcription factor OTF-1 and other cellular proteins. Proc.
Natl. Acad. Sci. USA 85:6347–6451.
9. Goto, H., S. Motomura, A. C. Wilson, R. N. Freiman, Y. Nakabeppu, K.
Fukushima, M. Fujishima, W. Herr, and T. Nishimoto. 1997. A single-point
mutation in HCF causes temperature-sensitive cell-cycle arrest and disrupts
VP16 function. Genes Dev. 11:726–737.
10. Greaves, R. F., and P. O’Hare. 1990. Structural requirements in the herpes
simplex virus type 1 transactivator Vmw65 for interaction with the cellular
octamer-binding protein and target TAATGARAT sequences. J. Virol. 64:
2716–2724.
11. Henry, R. W., V. Mittal, B. Ma, R. Kobayashi, and N. Hernandez. 1998.
SNAP19 mediates the assembly of a functional core promoter complex
(SNAPc) shared by RNA polymerases II and III. Genes Dev. 12:2664–2672.
12. Herr, W., R. A. Sturm, R. G. Clerc, L. M. Corcoran, D. Baltimore, P. A.
Sharp, H. A. Ingraham, M. G. Rosenfeld, M. Finney, G. Ruvkun, and H. R.
Horvitz. 1988. The POU domain: a large conserved region in the mammalian
pit-1, oct-1, oct-2 and Caenorhabditis elegans unc-86 gene products. Genes
Dev. 2:1513–1516.
13. Herr, W., and M. A. Cleary. 1995. The POU domain: versatility in transcrip-
tional regulation by a flexible two-in-one DNA binding domain. Genes Dev.
9:1679–1693.
14. Herr, W. 1998. The herpes simplex virus VP16-induced complex: mecha-
nisms of combinatorial transcriptional regulation. Cold Spring Harbor Symp.
Quant. Biol. 63:599–607.
15. Holm, L., and C. Sander. 1993. Protein structure comparison by alignment of
distance matrices. J. Mol. Biol. 233:123–138.
16. Huang, C. C., and W. Herr. 1996. Differential control of transcription by
homologous homeodomain coregulators. Mol. Cell. Biol. 16:2967–2976.
17. Katan, M., A. Haigh, C. P. Verrijzer, P. C. van der Vliet, and P. O’Hare.
1990. Characterization of a cellular factor which interacts functionally with
Oct-1 in the assembly of a multiprotein transcription complex. Nucleic Acids
Res. 18:6871–6880.
18. Klemm, J. D., M. A. Rould, R. Aurora, W. Herr, and C. O. Pabo. 1994.
Crystal structure of the Oct-1 POU domain bound to an octamer site: DNA
recognition with tethered DNA-binding modules. Cell 77:21–32.
19. Kristie, T. M., J. H. LeBowitz, and P. A. Sharp. 1989. The octamer-binding
proteins form multi-protein-DNA complexes with the HSV aTIF regulatory
protein. EMBO J. 8:4229–4238.
20. Kristie, T. M., and P. A. Sharp. 1990. Interactions of the Oct-1 POU sub-
domains with specific DNA sequences and with the HSV a-trans-activator
protein. Genes Dev. 4:2383–2396.
21. Kristie, T. M., and P. A. Sharp. 1993. Purification of the cellular C1 factor
required for the stable recognition of the Oct-1 homeodomain by the herpes
simplex virus a-trans-induction factor (VP16). J. Biol. Chem. 268:6525–6534.
22. Kristie, T. M., J. L. Pomerantz, T. C. Twomey, S. A. Parent, and P. A. Sharp.
1995. The cellular C1 factor of the herpes simplex virus enhancer complex is
a family of polypeptides. J. Biol. Chem. 270:4387–4394.
23. LaBoissie`re, S., S. Walker, and P. O’Hare. 1997. Concerted activity of host
cell factor subregions in promoting stable VP16 complex assembly and prevent-
ing interference by the acidic activation domain. Mol. Cell. Biol. 17:7108–7118.
24. Lai, J.-S., M. A. Cleary, and W. Herr. 1992. A single amino acid exchange
transfers VP16-induced positive control from the Oct-1 to the Oct-2 homeo
domain. Genes Dev. 6:2058–2065.
25. Lai, J.-S., and W. Herr. 1997. Interdigitated residues within a small region of
VP16 interact with Oct-1, HCF, and DNA. Mol. Cell. Biol. 17:3937–3946.
26. Lambright, D. G., J. Sondek, A. Bohm, N. P. Skiba, H. E. Hamm, and P. B.
Sigler. 1996. The 2.0 A crystal structure of a heterotrimeric G protein.
Nature (London) 379:311–319.
27. Liu, Y., W. Gong, C. C. Huang, W. Herr, and X. Cheng. 1999. Crystal
structure of the conserved core of the herpes simplex virus transcriptional
regulatory protein VP16. Genes Dev. 13:1692–1703.
28. Marsden, H. S., M. E. M. Campbell, L. Haarr, M. C. Frame, D. S. Parris, M.
Murphy, R. G. Hope, M. T. Muller, and C. M. Preston. 1987. The 65,000-Mr,
DNA-binding and virion trans-inducing proteins of herpes simplex virus type
1. J. Virol. 61:2428–2437.
29. Misra, V., S. Walker, P. Yang, S. Hayes, and P. O’Hare. 1996. Conforma-
tional alteration of Oct-1 upon DNA binding dictates selectivity in differen-
tial interactions with related transcriptional coactivators. Mol. Cell. Biol.
16:4404–4413.
30. Nicholls, A., K. A. Sharp, and B. Honig. 1991. Protein folding and associa-
tion: insights from the interfacial and thermodynamic properties of hydro-
carbons. Protein. Struct. Funct. Genet. 11:281–293.
31. O’Hare, P. 1993. The virion transactivator of herpes simplex virus. Semin.
Virol. 4:145–155.
32. O’Hare, P., C. R. Goding, and A. Haigh. 1988. Direct combinatorial inter-
action between a herpes simplex virus regulatory protein and a cellular
octamer-binding factor mediates specific induction of virus immediate-early
gene expression. EMBO J. 7:4231–4238.
33. O’Reilly, D., O. Hanscombe, and P. O’Hare. 1997. A single serine residue at
position 375 of VP16 is critical for complex assembly with Oct-1 and HCF
and is a target of phosphorylation by casein kinase II. EMBO J. 16:2420–2430.
34. Pomerantz, J. L., T. M. Kristie, and P. A. Sharp. 1992. Recognition of the
surface of a homeo domain protein. Genes Dev. 6:2047–2057.
35. Sadowski, I., J. Ma, S. Triezenberg, and M. Ptashne. 1988. GAL4-VP16 is an
unusually potent transcriptional activator. Nature (London) 335:563–564.
36. Sondek, J., A. Bohm, D. G. Lambright, H. E. Hamm, and P. B. Sigler. 1996.
Crystal structure of a GA protein bg dimer at 2.1A resolution. Nature
(London) 379:369–374.
37. Stern, S., and W. Herr. 1991. The herpes simplex virus trans-activator VP16
recognizes the Oct-1 homeo domain: evidence for a homeo domain recog-
nition subdomain. Genes Dev. 5: 2555–2566.
38. Stern, S., M. Tanaka, and W. Herr. 1989. The Oct-1 homeodomain directs
formation of a multiprotein-DNA complex with the HSV transactivator
VP16. Nature (London) 341:624–630.
39. Sturm, R. A., G. Das, and W. Herr. 1988. The ubiquitous octamer-binding
protein Oct-1 contains a POU domain with a homeo box subdomain. Genes
Dev. 2:1582–1599.
40. Sturm, R. A., and W. Herr. 1988. The POU domain is a bipartite DNA-
binding domain. Nature (London) 336:601–604.
41. Tanaka, M., U. Grossniklaus, W. Herr, and N. Hernandez. 1988. Activation
of the U2 snRNA promoter by the octamer motif defines a new class of RNA
polymerase II enhancer elements. Genes Dev. 2:1764–1778.
42. Tanaka, M., and W. Herr. 1990. Differential transcriptional activation by
Oct-1 and Oct-2: interdependent activation domains induce Oct-2 phosphor-
ylation. Cell 60:375–386.
43. Thompson, C. C., and S. L. McKnight. 1992. Anatomy of an enhancer.
Trends Genet. 8:232–236.
44. Triezenberg, S. J., R. C. Kingsbury, and S. L. McKnight. 1988. Functional
dissection of VP16, the trans-activator of herpes simplex virus immediate
early gene expression. Genes Dev. 2:718–729.
45. Walker, S., S. Hayes, and P. O’Hare. 1994. Site-specific conformational
alteration of the Oct-1 POU domain-DNA complex as the basis for differ-
ential recognition by Vmw65(VP16). Cell 79:841–852.
46. Wall, M. A., D. E. Coleman, E. Lee, J. A. Iniguez-Lluhi, B. A. Posner, A. G.
Gilman, and S. R. Sprang. 1995. The structure of the G protein heterotrimer
Gia1b1g2. Cell 83: 1047–1058.
47. Wilson, A. C., R. N. Freiman, H. Goto, T. Nishimoto, and W. Herr. 1997.
VP16 targets an amino-terminal domain of HCF involved in cell cycle pro-
gression. Mol. Cell. Biol. 17: 6139–6146.
48. Wilson, A. C., K. LaMarco, M. G. Peterson, and W. Herr. 1993. The VP16
accessory protein HCF is a family of polypeptides processed from a large
precursor protein. Cell 74: 115–125.
49. Wilson, A. C., M. G. Peterson, and W. Herr. 1995. The HCF repeat is an
unusual proteolytic cleavage signal. Genes Dev. 9:2445–2458.
49a.Wysocka, J., Y. Liu, R. Kobayashi, and W. Herr. 2001. Developmental
cell-cycle regulation of Caenorhabditis elegans HCF phosphorylation. Bio-
chemistry 40:5786–5794.
50. Xiao, P., and J. P. Capone. 1990. A cellular factor binds to the herpes simplex
virus type 1 transactivator Vmw65 and is required for Vmw65-dependent
protein-DNA complex assembly with Oct-1. Mol. Cell. Biol. 10:4974–4977.
4712 BABB ET AL. MOL. CELL. BIOL.
 o
n
 January 22, 2014 by M
AIN LIBRARY
http://m
cb.asm
.org/
D
ow
nloaded from
 
